The A-LIST WMM Insights Series
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04466722|
Recruitment Status : Recruiting
First Posted : July 10, 2020
Last Update Posted : July 10, 2020
|Condition or disease|
|Alzheimer Disease Dementia Mild Cognitive Impairment|
To do this, UsAgainstAlzheimer's will identify and engage individuals who want to focus on brain health; individuals who are worried about their cognition; individuals who perceive themselves to be at risk for Alzheimer's disease (AD); individuals who may be at risk for AD due to self-identified confirmation of underlying disease pathology; individuals who self-identify as having a diagnosis of mild cognitive impairment (MCI) or of AD or another dementia; and those who self-identify as current or former caregivers of patients with Alzheimer's disease or another dementia to participate in the A-LIST Research Projects. Such participants will either already be - or will be invited to become - members of the A-LIST cohort, an online cohort of individuals ready and willing to engage in A-LIST WMM Insights Series (A-LIST members).
The A-LIST WMM Insights Series will enlist participants to offer insights into a range of issues relevant to Alzheimer's, including as examples issues pertinent to clinical trial design, regulatory submissions, other research strategies, payer value determinations, and care and services research. The A-LIST WMM Insights Series may seek information that in some instances will be marketing research or other research exempt from IRB oversight. However, when an individual A-LIST Research Project constitutes human subjects research consistent with governing law, IRB approval will be sought and obtained. Where questions exist whether an individual A-LIST Research Project constitutes human subject research, IRB determination will be solicited.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||10000 participants|
|Target Follow-Up Duration:||3 Years|
|Official Title:||A-LIST What Matters Most Insights Series|
|Actual Study Start Date :||August 15, 2018|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2021|
- Phenotypical Characteristics of Patients and Caregivers [ Time Frame: 3 years ]Online monthly surveys capture the burden and unmet needs for patients and caregivers of individuals with or at risk for Alzheimer's disease, other dementias, and mild cognitive impairment; also recruiting individuals interested in brain health.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04466722
|Contact: Virginia Biggar, BAfirstname.lastname@example.org|
|Contact: Theresa Frangiosa, MBAemail@example.com|
|United States, District of Columbia|
|Washington, District of Columbia, United States, 20043|
|Contact: Virginia Biggar, BA 301-452-1123 firstname.lastname@example.org|
|Principal Investigator: Theresa Frangiosa, MBA|
|Principal Investigator:||Theresa Frangiosa, MBA||UsAgainstAlzheimer's|